Applied Genetic Technologies (AGTC) Reaches $4.68 After 8.00% Up Move; 2 Analysts Bullish Reinsurance Group of America, (RGA)

May 25, 2018 - By Darrin Black

Reinsurance Group of America, Incorporated (NYSE:RGA) Logo

Among 11 analysts covering Reinsurance Group of America (NYSE:RGA), 2 have Buy rating, 1 Sell and 8 Hold. Therefore 18% are positive. Reinsurance Group of America had 33 analyst reports since November 17, 2015 according to SRatingsIntel. The stock of Reinsurance Group of America, Incorporated (NYSE:RGA) has “Sector Perform” rating given on Thursday, April 28 by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Hold” on Friday, October 27. The firm earned “Hold” rating on Friday, November 10 by Keefe Bruyette & Woods. The rating was initiated by Wells Fargo on Friday, September 23 with “Market Perform”. The stock of Reinsurance Group of America, Incorporated (NYSE:RGA) earned “Neutral” rating by Goldman Sachs on Tuesday, January 3. Credit Suisse initiated the shares of RGA in report on Friday, October 7 with “Neutral” rating. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Thursday, December 21 report. The stock of Reinsurance Group of America, Incorporated (NYSE:RGA) earned “Hold” rating by Wood on Friday, April 7. Goldman Sachs initiated the stock with “Sell” rating in Tuesday, November 17 report. Morgan Stanley maintained Reinsurance Group of America, Incorporated (NYSE:RGA) on Monday, November 13 with “Underweight” rating. See Reinsurance Group of America, Incorporated (NYSE:RGA) latest ratings:

25/04/2018 Broker: Credit Suisse Rating: Neutral New Target: $164 Initiates Coverage On
05/04/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $138 New Target: $135 Maintain
02/03/2018 Broker: UBS Rating: Neutral New Target: $168 Initiates Coverage On
09/01/2018 Broker: Wells Fargo Rating: Hold New Target: $160.0 Maintain
21/12/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $165.0 Maintain
08/12/2017 Broker: RBC Capital Markets Rating: Hold New Target: $165.0 Maintain

The stock of Applied Genetic Technologies Corporation (NASDAQ:AGTC) is a huge mover today! The stock increased 4.00% or $0.18 during the last trading session, reaching $4.68. About 111,330 shares traded or 24.37% up from the average. Applied Genetic Technologies Corporation (NASDAQ:AGTC) has declined 39.42% since May 25, 2017 and is downtrending. It has underperformed by 50.97% the S&P500.The move comes after 9 months positive chart setup for the $84.76 million company. It was reported on May, 25 by Barchart.com. We have $5.05 PT which if reached, will make NASDAQ:AGTC worth $6.78 million more.

Since February 16, 2018, it had 1 insider buy, and 2 sales for $471,431 activity. The insider Boot Arnoud W.A. sold 400 shares worth $62,104. MATSON – TIMOTHY T also bought $44,745 worth of Reinsurance Group of America, Incorporated (NYSE:RGA) on Tuesday, May 1. The insider Neemeh Alain sold 2,955 shares worth $454,072.

Another recent and important Reinsurance Group of America, Incorporated (NYSE:RGA) news was published by Seekingalpha.com which published an article titled: “Reinsurance Group of America’s (RGA) CEO Anna Manning on Q1 2018 Results – Earnings Call Transcript” on April 27, 2018.

Investors sentiment decreased to 1.16 in 2017 Q4. Its down 0.02, from 1.18 in 2017Q3. It fall, as 15 investors sold Reinsurance Group of America, Incorporated shares while 145 reduced holdings. 65 funds opened positions while 121 raised stakes. 57.73 million shares or 0.41% more from 57.50 million shares in 2017Q3 were reported. Ing Groep Nv holds 0.03% of its portfolio in Reinsurance Group of America, Incorporated (NYSE:RGA) for 9,718 shares. Envestnet Asset Mgmt reported 15,034 shares or 0.01% of all its holdings. 442,537 were accumulated by Hermes Invest Mgmt Ltd. Utd Ser Automobile Association has 50,345 shares for 0.02% of their portfolio. Ledyard Fincl Bank invested in 51 shares or 0% of the stock. Globeflex Lp has 0.29% invested in Reinsurance Group of America, Incorporated (NYSE:RGA). Blackrock reported 5.90M shares or 0.04% of all its holdings. Royal Bancshares Of Canada has 0.01% invested in Reinsurance Group of America, Incorporated (NYSE:RGA). Moreover, Citadel Limited Co has 0% invested in Reinsurance Group of America, Incorporated (NYSE:RGA) for 9,500 shares. Buckingham Cap Management owns 2,383 shares or 0.11% of their US portfolio. Great West Life Assurance Can stated it has 54,022 shares. State Of Wisconsin Inv Board reported 0.03% of its portfolio in Reinsurance Group of America, Incorporated (NYSE:RGA). Eagle Asset Mngmt Inc holds 0.05% or 55,478 shares in its portfolio. Balasa Dinverno And Foltz Lc holds 8,818 shares. Rmb Cap Mngmt Llc reported 0.01% of its portfolio in Reinsurance Group of America, Incorporated (NYSE:RGA).

Reinsurance Group of America, Incorporated engages in reinsurance business. The company has market cap of $9.69 billion. It offers individual and group life and health insurance products, including term life, credit life, universal life, whole life, group life and health, joint and last survivor insurance, critical illness, disability, and longevity products, as well as asset-intensive and financial reinsurance products. It has a 5.42 P/E ratio. The firm also provides reinsurance for mortality, morbidity, and lapse risk associated with products; and reinsurance for investment-related risks, as well as develops and markets technology solutions for the insurance industry.

The stock decreased 0.14% or $0.21 during the last trading session, reaching $150.1. About 130,657 shares traded. Reinsurance Group of America, Incorporated (NYSE:RGA) has risen 23.42% since May 25, 2017 and is uptrending. It has outperformed by 11.87% the S&P500.

Analysts await Applied Genetic Technologies Corporation (NASDAQ:AGTC) to report earnings on September, 12. They expect $-0.23 EPS, down 27.78% or $0.05 from last year’s $-0.18 per share. After $-0.45 actual EPS reported by Applied Genetic Technologies Corporation for the previous quarter, Wall Street now forecasts -48.89% EPS growth.

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company has market cap of $84.76 million. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It currently has negative earnings. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation.

Among 10 analysts covering Applied Genetic (NASDAQ:AGTC), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Applied Genetic had 24 analyst reports since July 22, 2015 according to SRatingsIntel. As per Tuesday, September 13, the company rating was downgraded by Roth Capital. The stock has “Buy” rating by Chardan Capital Markets on Sunday, August 30. The firm has “Neutral” rating by TH Capital given on Tuesday, September 13. The firm has “Outperform” rating given on Thursday, September 14 by BMO Capital Markets. The company was initiated on Friday, December 4 by Wells Fargo. The rating was initiated by Chardan Capital Markets with “Buy” on Wednesday, July 22. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, August 10 report. On Friday, March 18 the stock rating was initiated by Janney Capital with “Buy”. The firm earned “Outperform” rating on Tuesday, September 13 by Wedbush. The stock of Applied Genetic Technologies Corporation (NASDAQ:AGTC) earned “Buy” rating by TH Capital on Wednesday, November 9.

Reinsurance Group of America, Incorporated (NYSE:RGA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>